Table 4. Review of literature comparing previous studies assessing the effect of PLR or NLR on survival outcomes in cervical cancer patients.

*p-value < 0.05 was considered significant.

SCC: Squamous cell carcinoma; AC: Adenocarcinoma; CCRT: Concurrent chemoradiotherapy; BT: Brachytherapy; RH: Radical hysterectomy; PLND: Pelvic lymphadenectomy; NACT: Neoadjuvant chemotherapy; RT: Radiotherapy; F/B: Followed by; PLR: Neutrophil-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; OS: Overall survival; DFS: Disease-free survival; PFS: Progression-free survival; N/A: Not available; NS: Non-significant; LRR: Lower relative risk.

Study

Type of the study

Study duration

Sample size (N)

Stages

Histology

Treatment

PLR cut-off

NLR cut-off

Median follow-up period (months)

Univariate analysis

Multivariate analysis

PLR

NLR

PLR

NLR

Wang et al. [19]

Retrospective, single-center

1999-2010

111

IB2-IIB

All

NACT F/B RH+PLND

142.2

2.4

N/A

NS

NS

NS

NS

Zhang et al. [20]

Retrospective, single-center

2005-2008

460

I-II

SCC, AC

RH+PLND

150.9

2.2

69

NS

OS, PFS

NS

OS

Jain et al. [13]

Retrospective

2005-2013

56

I-IV

SCC

RT/CCRT

N/A

2.5

NR

N/A

OS, PFS

N/A

OS, PFS

Chen et al. [21]

Retrospective, single-center

2006-2009

407

IB1–IIA

All

Any

143.47 (OS) 152.02 (RFS)

2.09 (OS) 2.59 (RFS)

NR

OS, RFS, LMN

OS, RFS

OS, RFS, LMN

OS, RFS

Onal et al. [22]

Retrospective, single-center

2006-2014

235

IB2-IVA

SCC, AC

CCRT

133.02

3.03

31.7

OS

OS, PFS

NS

OS, PFS

Zhu et al. [11]

Retrospective, single-center

2003-2008

96

IA–IV

AC

RT/CCRT

158,

2.32

N/A

OS (III-IV)

OS, PFS

NR

NR

Choi et al. [12]

Retrospective, single-center

2012-2014

339

I-IV

SCC

RH+PLND

138.8

2.5

44

OS, PFS

NS

PFS

NS

Nuchpramool et al. [23]

Retrospective, single-center

2001-2016

484

IA2-IB1

All

RH+PLND

NS

NS

56.9

NS

NS

NS

NS

Holub and Biete [24]

Retrospective, single-center

2009-2016

151

I-IV

All

Any

210

3.8

43.8

OS

OS

NS

NS

Huang et al. [25]

Meta-analysis

2010-2013

2804

I-IV

All

Any

N/A

NR

N/A

N/A

OS, PFS

N/A

OS, PFS

Wu et al. [26]

Meta-analysis

2012-2016

2452

I-IV

All

Any

N/A

N/A

N/A

N/A

OS, PFS

N/A

OS, PFS

Ittiamornlert and Ruengkhachorn [27]

Retrospective, single-center

2006-2017

355

IVB

All

NACT

N/A

3.6

NR

N/A

OS, PFS

N/A

N/A

Trinh et al. [28]

Retrospective, single-center

2008-2019

99

I-IV

All

Any

186.93

1.65

48.9

NS

OS, PFS

NS

OS

Jonska-Gmyrek et al. [10]

Retrospective, single-center

2008-2018

148

I-IV

All

CCRT+BT

148.89

2.34

75

Combined NLR and PLR significantly associated with OS and DFS

Combined NLR and PLR significantly associated with OS and DFS

Du et al. [29]

Retrospective, single-center

2012-2017

203

I-IIA

SCC, AC, ASC

RH

N/A

3.75

NR

N/A

OS, PFS

N/A

NR

Sabyasachi et al. [30]

Retrospective, single-center

2017-2019

208

IB3-IIIC1

SCC

CCRT+BT

140.6

2.45

N/A

LRR

LRR

LRR

LRR

Zhao et al. [31]

Retrospective, single-center

2008-2018

202

I-IV

All

RT/CCRT

N/A

3.029

71

N/A

OS, PFS

N/A

OS, PFS

Gao et al. [32]

Retrospective, single-center

2001-2016

110

I–IV

All

RH+PLND

186.88

N/A

N/A

OS

N/A

OS

N/A

Jin et al. [33]

Retrospective, single-center

2012-2016

190

IB2-IVA

N/A

CCRT+BT

N/A

2.52

46

N/A

OS, PFS

N/A

OS, PFS

Kumar et al. [34]

Retrospective, single-center

2003-2017

1051

IB2-IVA

All

CCRT+BT

N/A

N/A

69

OS, DFS

N/A

OS, DFS

N/A